Le Lézard
Classified in: Health, Covid-19 virus
Subject: TRI

Beech Tree Labs selects Curavit Clinical Research for fully virtual COVID-19 clinical trial

PARK CITY, Utah, Sept. 18, 2020 /PRNewswire/ -- Beechtree Labs has chosen Curavit Clinical Research for a fully decentralized clinical trial to investigate a promising Covid-19 therapy.  The FDA-authorized phase 2 clinical study will evaluate the effect of Beech Tree's BTL-TML therapy on mean duration and severity of disease in 40 outpatients aged 60 years or older with underlying conditions. The study also assesses the safety of BTL-TML over 10 days of treatment and an additional four days of follow-up.

The trial is unique in that it is a fully decentralized clinical trial, made possible by applying virtual trial design protocols, digital telehealth technologies, electronic patient reported outcomes (ePRO), and full web and contact center patient support to eliminate the need for in-person office visits.

Thomas Hatch, Director of Business Development at Beech Tree said: "We chose Curavit because of their exclusive focus on designing and executing virtual trials.  We needed a company with Curavit's expertise in this important new discipline of clinical research in order to make this trial possible."  Joel Morse, CEO of Curavit added: "This is a unique opportunity to apply modern trial design and telehealth technologies to allow patients to participate in this study without the potential risk of traveling to physical sites and to participate from the safety and comfort of their own homes."

Curavit is a new type of clinical research company that designs and executes decentralized - also called "virtual" - clinical trials.  Curavit brings together the world's leading researchers, enrolls previously untapped and underserved patient populations, applies machine learning algorithms to health and social engagement information, and leverages leading telehealth, patient data platform, and medical device technologies. Connect: https://www.linkedin.com/company/curavit/  Follow: https://twitter.com/CuravitClinical

Located in Providence, RI, Beech Tree Labs, Inc. (BTL) focuses on the discovery and early development of therapeutic agents that address a spectrum of unmet medical needs. The company has an extensive portfolio of patented formulations for products intended to treat such disorders as urinary incontinence, allergies, benign prostatic hypertrophy, anxiety, chronic obstructive pulmonary disease and herpesvirus infections.  BTL has conducted over 15 FDA- authorized phase 2 trials and has out-licensed both technology and products.

The current FDA-approved Phase II pilot study is taking place in Draper, Utah at Intermountain Clinical Research. Additional sites will open in the future. To learn more about this study:

SOURCE Curavit Clinical Research

These press releases may also interest you

at 06:05
Teladoc Health announced today the launch of Mental Health Care, its new telemedicine service enabling employees to count on convenient, stigma-free access to high-quality psychiatrists, psychologists and therapists from the convenience of their...

at 06:01
As Movember heads into their busiest fundraising moment of the year, the leading global men's health charity, announced their top corporate partners for 2020....

at 06:00
During a period when families are spending more time together than ever before, new research indicates a positive impact on behavioral and nutritional health. ...

at 06:00
Renowned cannabis industry website WayofLeaf.com has announced the launch of an interactive online tool that instantly searches and locates global cannabis dispensaries and CBD stores according to a user's specific geographic location. The...

at 06:00
Highly reputable American CBD company PremiumJane has announced several high-potency additions to their range of USA-made CBD gummies and oil tinctures. Among the brand's selection of new products will include a 1500mg CBD gummies option, as well as...

at 06:00
Thermo Fisher Scientific Inc. , the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2020. Third Quarter 2020 Highlights Third quarter revenue increased 36% to $8.52 billion. Third...

News published on 18 september 2020 at 05:25 and distributed by: